Loading...
  • Patients
  • To determine whether recombinant human granulocyte colony-stimulating factor (G-CSF) is effective in increasing neutrophil counts in patients with hairy cell leukemia and neutropenia. (annals.org)
  • Granulocyte colony-stimulating factor may increase neutrophil counts within 2 weeks in patients with hairy cell leukemia and neutropenia. (annals.org)
  • In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 10 9 /l and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. (medicines.org.uk)
  • Filgrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 10 9 /l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. (medicines.org.uk)
  • episodes of neutropenia
  • During episodes of neutropenia, affected individuals may experience fever, a general feeling of ill health (malaise), inflammation and ulceration of the mucous membranes of the mouth (stomatitis), inflammation of the throat (pharyngitis), inflammation and degeneration of the tissues that surround and support the teeth (periodontal disease), and/or loss of appetite. (rarediseases.org)
  • The episodes of neutropenia are apparent at birth or soon afterward. (wikipedia.org)
  • patients
  • On average, adult cancer patients who were treated at a hospital because of neutropenia stayed about three days longer and paid about $5,700 more than adult cancer patients who went to the hospital for other reasons. (cdc.gov)
  • Both adult and child cancer patients who were treated at a hospital for neutropenia were more likely to be admitted through the hospital's emergency room than cancer patients who were treated at a hospital for other reasons. (cdc.gov)
  • The Multinational Association for Supportive Care in Cancer (MASCC) risk index can be used to identify low-risk patients (score ≥21 points) for serious complications of febrile neutropenia (including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications). (wikipedia.org)
  • A prospective trial demonstrated that a modified MASCC score can identify patients with febrile neutropenia at low risk of complications, as well. (wikipedia.org)
  • In contrast, the Clinical Index of Stable Febrile Neutropenia (CISNE) score is specific of patients with solid tumors and seemingly stable episodes. (wikipedia.org)
  • Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study. (wikipedia.org)
  • A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. (wikipedia.org)
  • In 80 percent of patients, neutropenia persisted for 7 to 24 months. (wikipedia.org)
  • 2018
  • Participants in the 2018 Neutropenia Family Conference will have a chance to speak with the experts, hear presentations covering the latest treatment and research, and participate in programs geared toward managing life with neutropenia in it. (volunteermatch.org)